TidalHealth Peninsula Regional, Inc.

Salisbury, Maryland 21804

3 studies enrolling now · 18 studies all time

What they study most

ASCVD, Acute Coronary Syndrome, Advanced Cancer, Amyotrophic Lateral Sclerosis, Atherosclerotic Cardiovascular Disease, Atrial Fibrillation, COVID-19, Cancer, Carcinoma, Non-Small-Cell Lung, Coronary Heart Disease (CHD), Covid19, Dyslipidemias

Studies at this site

• Impact of Physical Functioning on Patient-Reported Outcomes in ALS Patients at TidalHealth — Recruiting now
• Knee Related Subchondral Bone Lesions Treated With IOBP — Recruiting now
• Community Health Worker Based Intervention to Improve Palliative Care — Enrolling by invitation
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
• A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome — Completed
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke — Completed
• NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC — Stopped early
• Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial — Running, not enrolling
• A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD) — Completed
• Personalized Therapy Study - HFRS (TriageHF) Post Approval Study — Running, not enrolling
• Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome — Completed
• Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies — Completed
• Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF) — Completed
• Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia — Completed
• Study of Sargramostim in Patients With COVID-19 — Completed
• Sargramostim Use in COVID-19 to Recover Patient Health — Completed
• The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS) — Stopped early